• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Oncology letters >Partial response of liver metastases treated with abiraterone in castration-resistant prostate cancer: A case report
【24h】

Partial response of liver metastases treated with abiraterone in castration-resistant prostate cancer: A case report

机译：阿比特龙治疗去势抵抗性前列腺癌肝转移的部分反应：一例报告

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Docetaxel is the current first-line treatment for castration-resistant prostate cancer (CRPC), following failure to respond to maximal androgen blockade (MAB). Patients who fail to respond to docetaxel may receive cabazitaxel or abiraterone; however, there are no recommendations on which of these two agents should be used first. Here, we present a case of a male patient suffering from CRPC with liver and lymph node metastases, in which abiraterone achieved a partial response, according to RECIST criteria. In the literature, visceral involvement in patients with advanced prostate cancer is an infrequent occurrence; it affects 18-22% of patients. In the pivotal study concerning docetaxel-resistant patients, abiraterone was compared with a placebo and the forest plot for survival demonstrated that patients with visceral involvement have significantly benefited from abiraterone. In the TROPIC trial comparing cabazitaxel with mitoxantrone, the proportion of patients with visceral disease was ~25% in both arms and there was no difference in overall survival in this subgroup of patients. In our case, we observed a significant activity of abiraterone in lymph node and liver metastases. If confirmed in large studies, this observation may raise concerns over whether to treat patients suffering from CRPC and visceral metasis with chemotherapy or hormone therapy.
机译：多西他赛是目前对抗去势抵抗性前列腺癌（CRPC）的一线治疗方法，对最大的雄激素阻断（MAB）没有反应。对多西紫杉醇无反应的患者可以接受卡巴他赛或阿比特龙;但是，没有建议先使用这两种代理中的哪一种。在这里，我们介绍了一名男性患者，患有CRPC并伴有肝和淋巴结转移，根据RECIST标准，阿比特龙可部分缓解。在文献中，晚期前列腺癌患者的内脏受累很少见。它影响了18-22％的患者。在一项关于多西他赛耐药患者的关键研究中，阿比特龙与安慰剂进行了比较，森林生存率证明，内脏受累的患者从阿比特龙中受益匪浅。在比较卡巴他赛与米托蒽醌的TROPIC试验中，两臂内脏疾病患者的比例约为25％，该亚组患者的总生存率无差异。在我们的案例中，我们观察到了阿比特龙在淋巴结和肝转移中的显着活性。如果在大型研究中得到证实，则该观察结果可能引起对是否应通过化学疗法或激素疗法治疗患有CRPC和内脏转移的患者的担忧。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号